Compass Laboratory Services LLC

Compass Laboratory Services LLC was paid $11.61M by Medicaid between Jan 2018 and Dec 2024, across 84 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 18% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Tennessee

Rank by total paid#11 of 70

Median peer was paid$141K

This provider vs. median82×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	26,829	$1.32M
2019	26,541	$1.47M
2020	35,747	$1.82M
2021	70,596	$2.14M
2022	47,240	$2.07M
2023	41,350	$1.62M
2024incomplete	27,872	$1.15M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	18%	39,133	29,125	$2.08M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	17%	21,180	19,729	$1.92M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	16%	17,536	15,850	$1.85M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	13%	27,903	24,748	$1.51M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	10%	34,474	29,697	$1.18M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	8.1%	8,207	6,840	$943K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	5.1%	15,482	13,950	$590K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.7%	1,872	1,770	$317K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.9%	2,445	2,328	$222K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.4%	16,922	13,635	$166K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.1%	5,252	4,791	$127K
87581		1.0%	4,841	4,429	$120K

72 more codes

G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	14,066	$103K
87631		<1%	717	$41K
87653		<1%	2,195	$38K
80361		<1%	2,860	$22K
80346		<1%	2,705	$21K
80354		<1%	3,093	$21K
80356		<1%	2,285	$20K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	473	$18K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	601	$17K
80348		<1%	2,305	$17K
80358		<1%	2,271	$15K
87640		<1%	867	$14K
87634		<1%	361	$14K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	126	$13K
80353		<1%	2,251	$13K
80355		<1%	2,397	$12K
80365		<1%	2,413	$12K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	631	$10K
80324		<1%	1,532	$10K
80373		<1%	2,716	$10K
80360		<1%	2,184	$9K
80359		<1%	1,862	$9K
80366		<1%	2,139	$8K
80363		<1%	1,557	$8K
80338		<1%	1,388	$7K
87500		<1%	428	$7K
87641		<1%	414	$7K
80345		<1%	1,237	$6K
80323		<1%	1,005	$6K
87481		<1%	228	$6K
80333		<1%	1,122	$6K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	233	$5K
80335		<1%	1,038	$5K
80370		<1%	1,489	$5K
80372		<1%	1,640	$5K
80343		<1%	1,187	$5K
80349		<1%	1,351	$4K
80368		<1%	1,700	$4K
80364		<1%	959	$4K
83992		<1%	1,656	$4K
80325		<1%	806	$4K
80339		<1%	1,061	$4K
80367		<1%	1,264	$4K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	134	$3K
87563		<1%	204	$2K
80321		<1%	395	$892.10
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	25	$861.84
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	867	$357.43
80336		<1%	92	$263.07
80053	Comprehensive metabolic panel	<1%	678	$236.84
80369		<1%	144	$143.90
83036	Hemoglobin; glycosylated (A1C)	<1%	250	$109.63
87086	Culture, bacterial; quantitative colony count, urine	<1%	27	$80.00
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	195	$64.06
82728		<1%	16	$59.09
84443	Thyroid stimulating hormone (TSH)	<1%	328	$57.56
83540		<1%	16	$56.40
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	684	$42.06
80048	Basic metabolic panel (calcium, ionized)	<1%	123	$39.50
80061	Lipid panel	<1%	322	$28.24
36415	Collection of venous blood by venipuncture	<1%	1,050	$20.31
80332		<1%	20	$15.36
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	198	$14.22
84439		<1%	87	$8.12
84481		0%	25	$0.00
80362		0%	28	$0.00
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	0%	68	$0.00
80342		0%	18	$0.00
83735		0%	28	$0.00
82550		0%	17	$0.00
82746		0%	27	$0.00
82607		0%	49	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHANDORF, CHARLES (LAB DIRECTOR)